Heterocyclic Carbon Compounds Containing A Hetero Ring Having Chalcogen (i.e., O,s,se Or Te) Or Nitrogen As The Only Ring Hetero Atoms Doai Patents (Class 514/183)
  • Patent number: 11364203
    Abstract: Disclosed are processes for forming compositions comprising small domains of an active agent and a matrix material, and methods of using them. A suspension of an active agent, a matrix material, a first solvent, and a second solvent is formed at a temperature T1, heated to a temperature T2 and spray dried.
    Type: Grant
    Filed: October 5, 2015
    Date of Patent: June 21, 2022
    Assignee: Bend Reserch, Inc.
    Inventors: David Thomas Vodak, Dwayne Thomas Friesen
  • Patent number: 11365183
    Abstract: The present invention provides compounds (n-3 PUFA derivatives) of formula (I): that modulate conditions associated with cardiac damage, especially cardiac arrhythmias.
    Type: Grant
    Filed: March 25, 2019
    Date of Patent: June 21, 2022
    Assignees: MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN, BOARD OF REGENTS OF UNIVERSITY OF TEXAS SYSTEM
    Inventors: Wolf-Hagen Schunck, Gerd Wallukat, Robert Fischer, Cosima Arnold, Dominik N. Mueller, Narender Puli, John R. Falck
  • Patent number: 11351187
    Abstract: Methods of treating, reducing the incidence of, and/or preventing an ischemic event in a patient undergoing percutaneous coronary intervention (PCI), comprising administering to the patient a pharmaceutical composition comprising cangrelor. The method may further comprise administering an additional therapeutic agent to the patient, the additional therapeutic agent comprising a P2Y12 inhibitor. Pharmaceutical compositions useful for treating, reducing the incidence of, and/or preventing an ischemic event in a patient undergoing PCI. The pharmaceutical compositions comprise cangrelor. Methods of preparing a pharmaceutical composition for treating, reducing the incidence of, and/or preventing an ischemic event in a patient undergoing PCI, comprising admixing cangrelor with one or more pharmaceutically acceptable excipients. An ischemic event may include stent thrombosis, myocardial infarction, ischemia-driven revascularization, and mortality.
    Type: Grant
    Filed: August 2, 2016
    Date of Patent: June 7, 2022
    Assignee: Chiesi Farmaceutici S.p.A.
    Inventors: Clive Arthur Arculus-Meanwell, Simona Skerjanec, Jayne Prats
  • Patent number: 11339126
    Abstract: Provided herein are novel lipase inhibitors and methods for using the same to treat inflammation, multisystem organ failure, necrotic pancreatic acinar cell death, acute pancreatitis, sepsis (e.g., culture negative sepsis), burns, and acne. For example, provided herein are two novel lipase inhibitors useful in the methods described herein: or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: July 12, 2018
    Date of Patent: May 24, 2022
    Assignees: Mayo Foundation for Medical Education and Research, Nanosyn, Inc.
    Inventors: Vijay P. Singh, Sampath-Kumar Anandan, Kevin Greenman, Zeeshan Kamal
  • Patent number: 11338140
    Abstract: Provided herein are methods, devices, compositions, and kits for monitoring neuromodulation efficacy based on changes in the level or activity of one or more target biomarkers. One aspect includes a comparison of baseline and post-modulation levels of one or more biomarkers in bodily fluid that have each been collected from a human subject at a relevant time, and that may be used to assess the neuromodulation efficacy. The post-neuromodulation levels for the one or more biomarkers may be collected from the human subject within about 5 minutes to about 14 days post-neuromodulation.
    Type: Grant
    Filed: August 3, 2017
    Date of Patent: May 24, 2022
    Assignee: MEDTRONIC ARDIAN LUXEMBOURG S.A.R.L.
    Inventors: Ayala Hezi-Yamit, Rudy Beasley, Susan Edwards, Lori Garcia, Michele Lee Silver, Christopher W. Storment, Carol M. Sullivan, Joseph A. Traina, Stefan Stoyanov Tunev
  • Patent number: 11278521
    Abstract: Provided herein are compounds that can bind GAS5 long non-coding RNA, compositions thereof, and uses thereof.
    Type: Grant
    Filed: December 15, 2016
    Date of Patent: March 22, 2022
    Assignees: UNIVERSITY OF SOUTH FLORIDA, THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS OFFICE OF GENERAL COUNSEL—PSG IV (024)
    Inventors: Niketa A. Patel, Jianfeng Cai
  • Patent number: 11274110
    Abstract: A process for preparing the benzothiophen-2-yl boronate of formula (VI) which serves as an intermediate for production of medicaments and for production of medicaments for treatment and/or prophylaxis of proliferative disorders, such as cancer and tumor diseases.
    Type: Grant
    Filed: October 18, 2018
    Date of Patent: March 15, 2022
    Assignee: Bayer Pharma Aktiengesellschaft
    Inventors: Jörg Gries, Johannes Platzek
  • Patent number: 11273151
    Abstract: The present invention relates to methods of treating a tumor or treating cancer in a subject having a p53 DNA contact mutation that involve administering, to the subject, a ROCK inhibitor. Also disclosed is a method of identifying a subject as a candidate for such treatment.
    Type: Grant
    Filed: November 3, 2016
    Date of Patent: March 15, 2022
    Assignee: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
    Inventors: Stuart Aaronson, Albino Troilo, Davide Esposito
  • Patent number: 11248001
    Abstract: The invention relates to novel heteroaryl compounds of Formula (I) and pharmaceutical preparations thereof. The invention further relates to methods of treating or preventing cardiovascular diseases, and methods treating sepsis or septic shock, using the novel heterocyclic compounds disclosed herein.
    Type: Grant
    Filed: January 16, 2020
    Date of Patent: February 15, 2022
    Assignee: AstraZeneca AB
    Inventors: Michael H. Serrano-Wu, Mark Chambers, Erica Goldsmith, Jason Tierney, Karamjit Jandu, David Clark, Paul Hinchliffe
  • Patent number: 11234954
    Abstract: Methods of treating sleep disorders, particularly certain aspects of insomnia, in elderly patients (65 years and older) by administering initial daily dosages of doxepin of 1-3 mg. These ultra-low initial dosages are more effective in elderly versus non-elderly patients in decreasing wake time during sleep, latency to persistent sleep and wake time after sleep, and are particularly efficacious in treating those conditions in the last hour of an 8-hour sleep cycle. Also, the dosages described herein are safe for elderly individuals.
    Type: Grant
    Filed: July 1, 2015
    Date of Patent: February 1, 2022
    Assignee: Currax Pharmaceuticals LLC
    Inventors: Roberta L. Rogowski, Susan Ellen Dube, Philip Jochelson, Neil Barton Kavey
  • Patent number: 11214553
    Abstract: Disclosed is a method for preparing 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) of formula (II), comprising the following steps: carrying out an alkylation reaction on cyclen in formula (I) and XCH2COOR in the presence of an acid-binding agent in water; adjusting a pH value to separate out a crude product of DOTA; and recrystallizing. The preparation method of the present invention is applicable to large-scale industrial production of DOTA, the whole process does not need to adopt an ion-exchange resin or low-temperature refrigeration mode for purification, and the purity and yield of the product are higher.
    Type: Grant
    Filed: September 18, 2017
    Date of Patent: January 4, 2022
    Assignee: VIWIT PHARMACEUTICAL CO., LTD.
    Inventors: Zhoujun Meng, Yigang He, Yanjun Wei, Yanping Xing
  • Patent number: 11208396
    Abstract: This invention relates to compounds that are agonists of the muscarinic M1 and/or M4 receptor and which are useful in the treatment of diseases mediated by the muscarinic M1 and M4 receptors. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula (I) where p; q; X1; X2; Y; R1; R2; R3; R4; R5 and R6 are as defined herein.
    Type: Grant
    Filed: November 2, 2016
    Date of Patent: December 28, 2021
    Assignee: Heptares Therapeutics Limited
    Inventors: Giles Albert Brown, Benjamin Gerald Tehan
  • Patent number: 11203601
    Abstract: The present disclosure provides compounds of Formula (I), and salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof. The provided compounds may be useful for inhibiting kinases, e.g., glycogen synthase kinase 3 (GSK3). The provided compounds may be able to selectively inhibit GSK3a, as compared to GSK3P and/or other kinases. The present disclosure further provides pharmaceutical compositions, kits, and methods of use, each of which involve the compounds. The compounds, pharmaceutical compositions, and kits may be useful for treating diseases associated with aberrant activity of GSK3a (e.g., Fragile X syndrome, attention deficit hyperactivity disorder (ADHD), childhood seizure, intellectual disability, diabetes, acute myeloid leukemia (AML), autism, and psychiatric disorder).
    Type: Grant
    Filed: April 5, 2018
    Date of Patent: December 21, 2021
    Assignees: The Broad Institute, Inc., Biogen MA Inc.
    Inventors: Florence Fevrier Wagner, Michel Weiwer, Arthur J. Campbell, Joshua R. Sacher, Edward Holson, Brian Stuart Lucas, TeYu Chen
  • Patent number: 11186544
    Abstract: The disclosure relates to compounds of formula (I), which are formyl peptide 2 (FPR2) receptor agonists and/or formyl peptide 1 (FPR1) receptor agonists. The disclosure also provides compositions and methods of using the compounds, for example, for the treatment of atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases.
    Type: Grant
    Filed: June 8, 2018
    Date of Patent: November 30, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventors: Nicholas R. Wurtz, Pravin Sudhakar Shirude, Andrew Quoc Viet
  • Patent number: 11186588
    Abstract: The 6H-thieno[2,3-e][1,2,4]triazolo[3,4-c][1,2,4]triazepine derivatives or salts thereof of the present invention have BRD4 inhibitory activity, and thus, they are useful as medicaments, in particular, as prophylaxis and/or therapeutic agents for diseases associated with BRD4.
    Type: Grant
    Filed: May 31, 2018
    Date of Patent: November 30, 2021
    Assignee: AYUMI PHARMACEUTICAL CORPORATION
    Inventors: Hiroyuki Aono, Iwao Seki, Miwa Imamura, Tomomi Tanaka, Satoshi Shirae, Kenji Kawashima, Yusuke Yamazaki, Minoru Yamamoto
  • Patent number: 11155551
    Abstract: Derivatives of N,N-diethyl-N?-phenyl-piperazine, a silent agonist of the mammalian ?7 nicotinic acetylcholine receptor, are provided. These silent agonists control the desensitization state of the receptor. Further provided are pharmaceutical compositions that allow the administration of the silent agonists of the disclosure to a subject animal or human in need of treatment for a pathological condition arising from such as inflammation. The novel silent agonists also may be co-administered to a patient simultaneously or consecutively with a type II positive allosteric modulator to modulate the activity of the receptor.
    Type: Grant
    Filed: April 16, 2020
    Date of Patent: October 26, 2021
    Assignee: University of Florida Research Foundation, Inc.
    Inventors: Nicole Alana Horenstein, Roger Lee Papke, Marta Quadri
  • Patent number: 11154712
    Abstract: Provided herein are methods, devices and compositions for assessing neuromodulation efficacy based on changes in the level of one or more biomarkers in plasma or urine collected from a human subject following a renal neuromodulation procedure.
    Type: Grant
    Filed: August 28, 2015
    Date of Patent: October 26, 2021
    Assignee: MEDTRONIC ARDIAN LUXEMBOURG S.A.R.L.
    Inventors: Carol Sullivan, Stefan Tunev
  • Patent number: 11154558
    Abstract: The use of direct factor Xa inhibitors, administered in a dose sufficient to reduce the activity of factor Xa to about 25% less than normal or lower, has the effect of preventing the onset of atherosclerosis, and stabilizing atherosclerotic lesions, and preventing the occurrence or recurrence of atherosclerotic events.
    Type: Grant
    Filed: April 7, 2017
    Date of Patent: October 26, 2021
    Assignee: Adams Pharmaceuticals LLC
    Inventors: Jonathan Adams, Peter Jeffrey Adams
  • Patent number: 11154543
    Abstract: Methods of the invention treat, reduce, or reverse fibrosis of a bodily tissue by administering to the local affected tissue a composition comprising an inhibitor of p38 MAP kinase, which treatment leads to a reduction or reversal of fibrosis.
    Type: Grant
    Filed: October 17, 2016
    Date of Patent: October 26, 2021
    Assignee: The Schepens Eye Research Institute, Inc.
    Inventors: Xiaoqing Guo, James D. Zieske
  • Patent number: 11154525
    Abstract: The present invention refers to new purified compositions of long chain polyunsaturated fatty acids, or their salts or esters, characterized by being essentially free from other usually present—but structurally different—components, such as furan fatty acids, phytanic and pristanic acids, squalene, and some oligomers, as well as several “persistent” environmental pollutants, such as polychlorinated dibenzo-dioxins and polychlorinated dibenzo-furans, polychlorinated biphenyls, polybrominated diphenyl-ethers, polycyclic aromatic hydrocarbons, and others, which are also usually present and extremely toxic. The invention also refers to the purification method to obtain said compositions and the use thereof as food, food for special medical use, food and diet supplement, and drug.
    Type: Grant
    Filed: June 29, 2020
    Date of Patent: October 26, 2021
    Inventor: Tiberio Bruzzese
  • Patent number: 11147810
    Abstract: The present invention provides pharmaceutical composition of antineoplastic alkylating agent in oral suspension dosage form. The oral suspension composition comprises of alkylating agent with other pharmaceutical excipients such as vehicle, preservative, antioxidant, suspending agent, surfactant, sweetener and flavouring agent. The present invention is an oral suspension having improved stability and palatability. The present invention also provides oral solution with flavor that has masked bitter taste of the drug. Further, the present invention also provides a process for preparation thereof.
    Type: Grant
    Filed: March 12, 2018
    Date of Patent: October 19, 2021
    Assignee: FTF PHARMA PRIVATE LIMITED
    Inventors: Sandip Mehta, Manish Umrethia, Henil Patel, Jayanta Kumar Mandal
  • Patent number: 11142511
    Abstract: The present invention relates to a coumarin (keto) oxime ester compound of formula (I), wherein n and R1, R2, R3, R4, R5, R6, and R7 are as defined in the specification. The compound has strong ultraviolet absorption in the range of 300 to 450 nm. After absorbing light energy, it can quickly transfer energy and continuously initiate polymerization. It has obvious advantages in terms of photosensitivity and pattern integrity, and is very suitable for radiation curing by UV-LED light source. In addition, the compound of formula (I) also has good thermal stability. The present invention also relates to a method for preparing the compound of formula (I) and use of the compound. The compound is suitable as a photoinitiator in a UV-LED light curing system and is suitable for the radiation wavelength of UV-LED light curing.
    Type: Grant
    Filed: May 29, 2018
    Date of Patent: October 12, 2021
    Assignee: Hubei Gurun Technology Co., Ltd.
    Inventors: Yulian Pang, Yingquan Zou, Shuheng Fan, Ming Gao, Yangyang Xin
  • Patent number: 11136327
    Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein all the variables are as defined herein. These compounds are selective Factor XIa inhibitors or dual inhibitors of fXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
    Type: Grant
    Filed: November 21, 2019
    Date of Patent: October 5, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventors: James R. Corte, Tianan Fang, Carl P. Decicco, Donald J. P. Pinto, Karen A. Rossi, Zilun Hu, Yoon Jeon, Mimi L. Quan, Joanne M. Smallheer, Yufeng Wang, Wu Yang
  • Patent number: 11103497
    Abstract: The present invention provides 4-anilino-3-quinolinecarbonitriles compounds useful for treating a subject having an BcrAbl positive leukemia that is resistant to imatinib.
    Type: Grant
    Filed: May 30, 2008
    Date of Patent: August 31, 2021
    Assignee: Wyeth LLC
    Inventor: Becker Hewes
  • Patent number: 11083795
    Abstract: The invention provides an amorphous metal-organic framework for use in methods of treatment. The amorphous metal-organic framework may hold a component for delivery. The amorphous metal-organic framework is obtained or is obtainable by amorphization of a crystalline amorphous metal-organic framework holding the component. The amorphous metal-organic framework may be a zirconium-containing or a bismuth-containing metal-organic framework, such as a framework having arylcarboxylate ligands, such as benzenedicarboxylate ligands.
    Type: Grant
    Filed: June 24, 2016
    Date of Patent: August 10, 2021
    Assignee: Cambridge Enterprise Limited
    Inventors: Claudia Orellana-Tavra, Nigel Slater, David Fairen-Jimenez, Michelle Teplensky, Emma Baxter, Thomas Bennett, Anthony Cheetham
  • Patent number: 11065235
    Abstract: The present invention relates to substituted methanopyrido [2,1-a]isoindolones of formula I, wherein, R1 is selected from phenylsulfonyl or p-toluenesulfonyl; and n=1, 2, 3; their derivatives, stereoisomers, pharmaceutically acceptable salts and pharmaceutically acceptable compositions having potential muscarinic acetylcholine receptor modulator activity.
    Type: Grant
    Filed: May 18, 2018
    Date of Patent: July 20, 2021
    Assignees: Council of Scientific & Industrial Research, Centre for Biomedical Research
    Inventors: Ganesh Pandey, Rajesh Varkhedkar, Divya Tiwari, Prem Narayan Yadav, Shalini Dogra, Yusuf Hussain
  • Patent number: 11052070
    Abstract: Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.
    Type: Grant
    Filed: November 20, 2019
    Date of Patent: July 6, 2021
    Assignee: Biohaven Therapeutics Ltd.
    Inventors: Jay Edward Wrobel, Allen B. Reitz, Jeffery Claude Pelletier, Garry Robert Smith, Haiyan Bian
  • Patent number: 11046714
    Abstract: The present invention is directed to 2,2-difluorodioxolo compounds that are antagonists of A2A receptor. The present invention is also directed to uses of the 2,2-difluorodioxolo compounds described herein in the potential treatment or prevention of neurological disorders and diseases in which A2A receptor are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds and to uses of these pharmaceutical compositions in the prevention or treatment of such diseases in which A2A receptors are involved.
    Type: Grant
    Filed: August 25, 2014
    Date of Patent: June 29, 2021
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Ali Amjad, Gioconda V. Gallo, Timothy J. Henderson, Rongze Kuang, Yeon-Hee Lim, Michael Man-Chu Lo, Edward Metzger, Manuel de Lera Ruiz, Andrew Stamford, Paul Tempest, Brent Whitehead, Heping Wu
  • Patent number: 11045457
    Abstract: Disclosed are compounds of Formula 1, stereoisomers thereof, and pharmaceutically acceptable salts thereof, wherein L, r, s, R5, R6, R7, R9, R10, R11, R12, X1, X2, X3, X4, X13, and X14 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating diseases, disorders, and conditions associated with SSTR4.
    Type: Grant
    Filed: February 28, 2019
    Date of Patent: June 29, 2021
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Zacharia Cheruvallath, Jason Green, Ben Johnson, Kristin Schleicher, Huikai Sun, Mingnam Tang
  • Patent number: 11040984
    Abstract: Disclosed is a novel quinazoline compound. Specifically, disclosed are a compound represented by the formula (I) and a pharmacologically acceptable salt.
    Type: Grant
    Filed: December 29, 2017
    Date of Patent: June 22, 2021
    Assignee: MEDSHINE DISCOVERY INC.
    Inventors: Xile Liu, Charles Z. Ding, Shuhui Chen, Lingyun Wu, Lihong Hu, Haiwen Wan
  • Patent number: 11026909
    Abstract: A method for amelioriation of, or prophylaxis against, a viral infection comprising administering to a patient in need of treatment a therapeutically effective amount of 5 aminolevulinic acid, optionally with at least one of cucumarin nano, zinc, vitamin C and methylene blue, and compositions thereof. Such compositions may be used for the treatment of coronavirus infections, including the SARS-CoV-2 virus, and/or rhinoviruses.
    Type: Grant
    Filed: December 23, 2020
    Date of Patent: June 8, 2021
    Inventors: Nadimpally Satyavarahala Raju, Venkata Satya Suresh Attili, Nadimpally Neha Varma, Steven Jerome Moore, Cullen Thomas Moore
  • Patent number: 11020496
    Abstract: The present disclosure relates to compositions and methods for enhancing mosquito feeding.
    Type: Grant
    Filed: September 11, 2018
    Date of Patent: June 1, 2021
    Assignee: University of Central Florida Research Foundation, Inc.
    Inventors: Bradley Jay Willenberg, Sudipta Seal, Alexander John Bosak, Alicia Renae Willenberg
  • Patent number: 11013712
    Abstract: A composition comprising doxepin, or a pharmaceutically acceptable salt, or prodrug thereof, and a compound that enhances sleep onset, sleep maintenance or reduces early morning awakenings. These compositions are useful for treating multiple manifestations of insomnia.
    Type: Grant
    Filed: September 12, 2012
    Date of Patent: May 25, 2021
    Assignee: Currax Pharmaceuticals LLC
    Inventors: Philip Jochelson, Robert Mansbach, Michael Skinner, Neil B. Kavey
  • Patent number: 11007168
    Abstract: The invention relates to use of the trans-(E) isomer or isomeric mixtures containing specified ratios of the trans-(E) and cis-(Z) isomers of doxepin, metabolites of doxepin, pharmaceutically-acceptable salts of doxepin and prodrugs of the same; compositions containing the same, for the treatment of sleep disorders.
    Type: Grant
    Filed: December 2, 2019
    Date of Patent: May 18, 2021
    Assignees: Currax Pharmaceuticals LLC, ProCom One, Inc.
    Inventors: Susan E. Dubé, Neil B. Kavey
  • Patent number: 11000514
    Abstract: The technical field of the invention is in pharmaceutical compounds and methods. In an aspect, the disclosure provides macrolide compounds suitable for use as antifungal agents, as well as methods for their use and compositions containing the same.
    Type: Grant
    Filed: February 20, 2020
    Date of Patent: May 11, 2021
    Assignee: Duke University
    Inventors: Jonathan A. Covel, Mitchell Mutz, Peter J. Webb, Robert Remme Webb, II
  • Patent number: 10987329
    Abstract: The present invention provides therapeutic combinations of 5-aminolevulinic acid, with at least one of: Vitamin C, curcumin, zinc, and methylene blue for the treatment of coronavirus infections, including the SARS-CoV-2 virus, and/or rhinoviruses. Optionally such compositions may comprise other dietary supplements and one or more pharmaceutically acceptable excipients and also process for preparing it. The composition can also include other antiviral agents.
    Type: Grant
    Filed: July 2, 2020
    Date of Patent: April 27, 2021
    Inventors: Nadimpally Satyavarahala Raju, Venkata Satya Suresh Attili, Nadimpally Neha Varma, Steven Jerome Moore, Cullen Thomas Moore
  • Patent number: 10973934
    Abstract: The present invention relates to the RRR/SSS pair of enantiomers of the of Gd(PCTA-tris-glutaric acid), the single enantiomers of the pair, the pharmaceutically acceptable salts thereof, their amide derivatives, and compositions comprising at least 50% of these compounds.
    Type: Grant
    Filed: August 6, 2019
    Date of Patent: April 13, 2021
    Assignee: BRACCO IMAGING S.P.A.
    Inventors: Roberta Napolitano, Luciano Lattuada, Zsolt Baranyai, Nicole Guidolin, Giuseppe Marazzi
  • Patent number: 10973796
    Abstract: The present disclosure provides methods for treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof. In some embodiments, the method comprises lowering high sensitivity CRP (hs-CRP) levels in a subject including, for example, a subject with a HbA1c value of about 5.00%-8.50% or at least about 6.8%.
    Type: Grant
    Filed: October 24, 2017
    Date of Patent: April 13, 2021
    Assignee: Amarin Pharmaceuticals Ireland Limited
    Inventors: Mehar Manku, Ian Osterloh, Pierre Wicker, Rene Braeckman, Paresh Soni
  • Patent number: 10973874
    Abstract: The present disclosure relates to the control of fungal infection of horn-like envelopes covering dorsal and terminal phalanges in humans and animals and related cerebral protrusions in animals as well as keratin comprising material on surfaces of humans and animals. Agents and natural and synthetic formulations and extracts useful for the control of fungal infection of these envelopes and related protrusions and keratin comprising material are also encompassed by the subject disclosure. In an embodiment, the present disclosure teaches the treatment of fungal infection of nails and in particular onychomycosis in humans.
    Type: Grant
    Filed: April 21, 2017
    Date of Patent: April 13, 2021
    Assignee: Hexima Limited
    Inventors: Nicole Louise van der Weerden, Marilyn Anne Anderson
  • Patent number: 10968213
    Abstract: The present invention provides a compound having a lysine-specific demethylase-1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, developmental disorders, particularly diseases having intellectual disability (e.g., autistic spectrum disorders, Rett syndrome, Down's syndrome, Kabuki syndrome, fragile X syndrome, Kleefstra syndrome, neurofibromatosis type 1, Noonan syndrome, tuberous sclerosis), neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, spinocerebellar degeneration (e.g., dentatorubural pallidoluysian atrophy) and Huntington's disease), epilepsy (e.g., Dravet syndrome) or drug dependence, and the like. A compound represented by the formula wherein each symbol is as defined in the present specification, or a salt thereof.
    Type: Grant
    Filed: June 27, 2019
    Date of Patent: April 6, 2021
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Shigemitsu Matsumoto, Yasushi Hattori, Masashi Toyofuku, Shinji Morimoto, Masaki Daini, Takuto Kojima, Tomohiro Kaku, Mitsuhiro Ito
  • Patent number: 10959982
    Abstract: The present invention relates in part a to multiparticulate sprinkle dosage form comprising duloxetine or a pharmaceutically acceptable salt thereof, having higher acid resistance as compared to commercially available delayed release formulations. It further relates to various methods of administering the said multiparticulate sprinkle dosage forms.
    Type: Grant
    Filed: September 13, 2019
    Date of Patent: March 30, 2021
    Assignee: Sun Pharmaceutical Industries Limited
    Inventors: Ravindra Agarwal, Tarun Singhal, Ravi Kochhar
  • Patent number: 10954273
    Abstract: Provided are novel types of hybrid cyclic libraries that contain a known protein binding domain of a natural product. Also provided are synthetic methods to make such libraries and methods for the deconvolution of hits using partially split-pooled library compounds. Such methods are applicable for use with the entire human proteome to screen such libraries that bind and for the identification of hits.
    Type: Grant
    Filed: September 6, 2019
    Date of Patent: March 23, 2021
    Assignee: The Johns Hopkins University
    Inventors: Jun O. Liu, Jingxin Wang, Zufeng Guo, Wei Li, Shridhar Bhat, Manisha Das
  • Patent number: 10953019
    Abstract: A series of substituted fused pentacyclic imidazopyridine and imidazopyridazine derivatives, and analogues thereof, being potent modulators of human TNF? activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Grant
    Filed: March 14, 2018
    Date of Patent: March 23, 2021
    Assignees: UCB Biopharma SRL, Sanofi
    Inventors: Julien Alistair Brown, Daniel Christopher Brookings, Jag Paul Heer, James Andrew Johnson, Zhaoning Zhu
  • Patent number: 10954246
    Abstract: A crystalline form of Mod. I of Formula I: And, a process for the preparation of the crystalline form and a pharmaceutical use of the crystalline form.
    Type: Grant
    Filed: October 11, 2019
    Date of Patent: March 23, 2021
    Assignee: Taizhou EOC Pharma Co., Ltd.
    Inventors: Heting Li, Deqiang Wang, Wei Chang, Hongrui Yu, Xiaoming Zou
  • Patent number: 10947207
    Abstract: There are provided, inter alia, compounds and methods useful for the treatment of neurological conditions, such as neurological disorders and neurodegenerative diseases, including Alzheimer's Disease.
    Type: Grant
    Filed: August 4, 2017
    Date of Patent: March 16, 2021
    Assignee: The Regents of the University of California
    Inventors: Mohammad Parvez Alam, Varghese John, Patricia Spilman, Kanagasabai Vadivel
  • Patent number: 10919894
    Abstract: Compounds of formula (I): wherein: R1 is butoxy or methylbutoxy; R2 is a group having the structure: where n is an integer having a value of five; Het is a six-membered saturated heterocycle containing five carbon atoms and one nitrogen atom, wherein Het is attached to the —(CH2)n— moiety at the carbon 4 position of the heterocycle; and R3 is hydrogen; or pharmaceutically acceptable salts thereof; and their use as vaccine adjuvants and in the treatment of various disorders.
    Type: Grant
    Filed: January 17, 2020
    Date of Patent: February 16, 2021
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Helene G. Bazin-Lee, Yufeng Li
  • Patent number: 10888549
    Abstract: Methods for preventing or treating subjects having cancer based on the identification of pharmaceutical agents that target cancer stem cells (CSCs) have been identified. These methods include administering to the subject an effective amount of a COX2 inhibitor and an effective amount of a YAP1 inhibitor. In addition, methods of enhancing chemotherapeutic responses in cancer patients have been discovered and are described herein.
    Type: Grant
    Filed: March 7, 2017
    Date of Patent: January 12, 2021
    Assignee: The Johns Hopkins University
    Inventors: Mohammad O. Hoque, David Sidransky, Akira Oki
  • Patent number: 10875840
    Abstract: A method for catalytically converting a dihydrotetrazine 1 into a tetrazine 2, wherein one R group on the dihydrotetrazine 1 is a substituted or unsubstituted aryl, heteroaryl, alkyl, alkenyl, alkynyl, carbonyl, or heteroatom-containing group, and the other R group is selected from the group consisting of H and substituted or unsubstituted aryl, heteroaryl, alkyl, alkenyl, alkynyl, carbonyl,- or heteroatom-containing groups; 1, 2 wherein the method comprises oxidizing dihydrotetrazine 1 in a reaction medium in the presence of a catalyst and a stoichiometric oxidant.
    Type: Grant
    Filed: December 15, 2016
    Date of Patent: December 29, 2020
    Assignee: UNIVERSITY OF DELAWARE
    Inventors: Joseph Fox, Xinqiao Jia, Will Trout, Joel Rosenthal, Han Zhang, Yinzhi Fang, Colin Thorpe, Shuang Liu, Yixin Xie
  • Patent number: 10857120
    Abstract: The present disclosure provides a method for the treatment of Parkinson's disease comprising simultaneously or sequentially administering to a patient in need of treatment of Parkinson's disease a dosage form comprising (i) levodopa in an amount ranging from 50 mg to 300 mg, (ii) carbidopa in an amount ranging from 25 mg to 150 mg or a therapeutically equivalent amount of another aromatic amino acid decarboxylase inhibitor, and (iii) entacapone in an amount ranging from 50 mg to 300 mg, wherein the proportion of entacapone to carbidopa in said dosage form ranges from 0.3:1.0 to 3.2:1.0 by weight, a moderately potent COMT inhibitor in an amount ranging from 25 mg to 200 mg, wherein the proportion of said COMT inhibitor to carbidopa in said dosage form ranges from 0.16:1.0 to 3.08:1.0 by weight, or a highly potent COMT Inhibitor in an amount ranging from 1 mg to 100 mg, wherein the proportion of said COMT inhibitor to carbidopa in said dosage form ranges from 0.006:1.0 to 1.54:1.0 by weight.
    Type: Grant
    Filed: October 2, 2014
    Date of Patent: December 8, 2020
    Assignee: ORION CORPORATION
    Inventors: Juha Rouru, Mikko Kuoppamäki, Juha Ellmen, Pekka Männistö
  • Patent number: 10858306
    Abstract: The present invention concerns a method of synthesizing a iodo- or astatoarene comprising the reaction of a diaryliodonium compound with a iodide or astatide salt, respectively. The invention also relates to said iodo- or astatoarene and diaryliodonium compound as such. The invention also concerns a method of synthesizing a iodo- or astatolabelled biomolecule and/or vector using said iodo- or astatoarene.
    Type: Grant
    Filed: April 9, 2020
    Date of Patent: December 8, 2020
    Assignees: INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (INSERM), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE NANTES, UNIVERSITE D'ANGERS, THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: François Guerard, Jean-François Gestin, Martin W. Brechbiel, Yong-Sok Lee